E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic Lupus Erythematosus |
|
E.1.1.1 | Medical condition in easily understood language |
Systemic Lupus Erythematosus or SLE, is an inflammatory disease caused when the immune system attacks its own tissues. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042947 |
E.1.2 | Term | Systemic lupus erythematosus synd |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of BMS-986165 on the SRI(4) response at Week 32 in subjects with SLE |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of BMS-986165 on measures of global and organ-specific
SLE clinical response.
To assess the safety and tolerability of BMS-986165.
To assess the PK of BMS-986165 in subjects with SLE.
To assess the effect of BMS-986165 on PD markers.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Biomarker assessments substudy - a sample will be collected 24 to 72 hours after the first dose for for blood RNA and inflammatory markers - in USA only.
Blood flow cytometry substudy in approximately 120 subjects - in USA and Poland only. |
|
E.3 | Principal inclusion criteria |
1) Signed Written Informed Consent
2) SLE Disease Characteristics
a) Diagnosed ≥ 24 weeks before the screening visit
b) Meets the SLICC classification criteria for SLE.
c) One of the following: elevated antinuclear antibodies ≥ 1:80 or
positive anti-dsDNA( positive includes indeterminate results) or positive
anti-Smith as determined by the central laboratory.
d) Total SLEDAI-2K score ≥ 6 points and clinical SLEDAI-2K score ≥ 4
points with joint involvement and/or rash
o Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers
cannot count toward the points required for screening at entry.
o Clinical SLEDAI-2K excludes laboratory abnormalities such as
hematuria, pyuria, urinary casts, proteinuria, positive anti-dsDNA,
decreased complement,
thrombocytopenia, and leukopenia.
e) At least 1 of the following BILAG-based protocol-specific
manifestations of SLE:
i) BILAG A or B grade in the Mucocutaneous body system. If a BILAG B
grade for
Mucocutaneous disease is due to BILAG #6 mild skin eruption, the total
score of the erythema and scale components of the CLASI disease
activity must be ≥ 3 (excluding mucous membrane ulcerations and
nonscarring alopecia).
ii) Modified BILAG A or B score in the Musculoskeletal body system due
to active
polyarthritis.
iii) If only 1 B and no A grade is present in the Mucocutaneous body
system or in the Musculoskeletal body system due to arthritis, then at
least 1 B grade must be present in one of the other body systems, for a
total of 2 BILAG B body system grades.
3) Medications for SLE
a) Background therapy is required for ≥ 12 weeks before the screening
visit and must be at a stable dose for ≥ 8 weeks before the screening
visit and remain stable until randomization and throughout study
participation. Details for specific medications are as follows:
Immunosuppressants (combinations of these are NOT permitted):
o azathioprine (maximum 200 mg/day)
o 6-mercaptopurine (6-MP)
o methotrexate (MTX; maximum 25 mg/week; dose and route of
administration
of MTX may not be changed for 8 weeks before the screening visit and
throughout study participation)
o leflunomide
o mycophenolate mofetil/ mycophenolic acid (MMF). Note: Subjects who
are
receiving MMF may participate in the study only if administered as a
maintenance therapy and up to a maximum of 2 g/day (or equivalent);
in subjects of African ancestry, 3 g/day (or equivalent) is acceptable.
Treatment may be interrupted due to neutropenia per the product label.
Antimalarials: chloroquine, hydroxychloroquine, or quinacrine;
monotherapy is permitted.
Required discontinuation periods for other immunomodulatory drugs
or biologic drugs (are provided in Appendix 7 of the protocol.
b) CS (prednisone or equivalent) background therapy is permitted but
not required. For subjects taking CS, the dose must be stable for ≥ 2
weeks before the screening visit, cannot exceed 30 mg/day at screening,
and must remain stable until randomization. Prednisone equivalents are
provided in Appendix 6. Further specifications are as follows:
Intramuscular, intra-articular, intrabursal, and intravenous (IV) CS
use is prohibited within 6 weeks before screening.
Topical CS use is permitted, but must follow a stable regimen
throughout the study and cannot be used on an as-needed basis.
Inhaled CS for nonlupus conditions is permitted and will not count
against the
maximum CS dose.
Modified-release CS formulations are prohibited.
c) Requirements for subjects who are receiving chronic therapy with
NSAIDs (including marketed cyclooxygenase -2 inhibitors) are as follows; exceptions or changes may be possible with approval by the
medical monitor:
Doses must be stable for 14 days before the screening visit and must
remain stable until randomization and throughout the study.
No more than 1 oral NSAID may be used (at a stable dose) during the
study, and may be combined with topical NSAIDs.
Use of 1 or more topical NSAIDs is permitted, but must follow a stable
regimen throughout the study.
4) Age and Reproductive Status
a) Men and women, ages 18 to 75 years, inclusive, at the time of
screening
b) Women of childbearing potential must have a negative serum or urine
pregnancy test within 24 hours prior to the start of study treatment.
c) Women must not be breastfeeding
d) WOCBP must agree to follow instructions for method(s) of
contraception for the duration of treatment with study treatment (BMS-
986165 or placebo) for a total of 33 days post treatment completion.
e) WOCBP who are not heterosexually active are exempt from
contraceptive requirements, and still must undergo pregnancy testing as
described
f) Investigators shall counsel WOCBP and men on pregnancy prevention
and the
implications of an unexpected pregnancy and methods of contraception.
g) Men must follow contraception instructions and refrain from sperm
donation as indicated. |
|
E.4 | Principal exclusion criteria |
1) Target Disease Exceptions
a) Drug-induced SLE
b) Other autoimmune diseases are excluded.
c) SLE overlap syndromes such as scleroderma and mixed connective
tissue disease are excluded.
d) Subjects with a serious thrombotic event or unexplained pregnancy
loss within 1 year before the screening visit. Subjects with a history of
catastrophic antiphospholipid syndrome or saddle embolism and history
of pregnancy losses.
e) Active or unstable lupus neuropsychiatric manifestations, including
but not limited to any condition defined by BILAG A criteria.
f) Active, severe lupus nephritis that requires or may require treatment
with cytotoxic agents or high-dose CS.
2) Other Medical Conditions:
a)Women who are pregnant or breastfeeding
b) Any major illness/condition that will increase the risk with
participation in the study
c) Any major surgery within the last 30 days before the first dose of
study treatment or planned during the study.
d) Cancer or history of cancer or lymphoproliferative disease within 5
years
e) Class III or IV congestive heart failure
f) Acute coronary syndrome and/or any history of significant
cerebrovascular disease within 24 weeks of screening
g) Current or recent (within 3 months pre-randomization)
gastrointestinal disease, including surgery, that could impact the
absorption of study treatment
h) Subjects with non-SLE concomitant illness that is likely to require
additional systemic glucocorticosteroid therapy
i) Significant blood loss or blood transfusion within 4 weeks of
randomization
j) Inability to tolerate oral medication
k) Inability to undergo venipuncture and/or tolerate venous access
l) Recent (within 6 months of randomization) drug or alcohol abuse.
3) Prior/Concomitant Therapy
a) Inability to comply with restrictions and prohibited treatments or with
discontinuation requirements.
b) Taking more than 1 immunosuppressant.
c) Prior exposure to Tyk2 inhibitors
d) Prior exposure to anifrolumab, rontalizumab or ustekinumab
e) Other investigational agents must be discontinued at least 12 weeks
or 5 half-lives before randomization, whichever is longer.
4) Findings Related to Possible Infection
a) Evidence of active or latent tuberculosis (TB):
Positive chest x-ray for evidence of active pulmonary TB within 6
months pre-screening (some exceptions allowed)
b) Hepatitis C, hepatitis B, or HIV infection as demonstrated by a
positive blood screen for hepatitis C antibody (anti-HCV), hepatitis B
surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or HIV-1
and -2 antibody.
c) Currently on any therapy for chronic infection
d) History of congenital or acquired immunodeficiency
e) Known active infection, or any major episode of infection requiring
hospitalization or treatment with parenteral antimicrobial agents within
30 days of randomization, or completion of oral antimicrobial agents
within 2 weeks of randomization
f) Previous history of herpes zoster, herpes simplex, or influenza
infection within 12 weeks of randomization or a history of
disseminated/complicated herpes zoster infection
g) Administration of a live vaccine within 90 days or an inactivated
vaccine within 30 days of randomization. Furthermore, live vaccines
should not be used during treatment or within the 2 months following
last dose, and any other inactivated vaccines should be used according
to local guidelines.
5) Physical and Laboratory Test Findings
a) Clinically significant abnormalities on chest X-ray or ECG
b) Clinically significant abnormalities in laboratory tests:
i) Serum alanine aminotransferase (ALT) > 2× ULN, unless related to
lupus
ii) Serum aspartate aminotransferase (AST) > 2× ULN, unless related to
lupus
iii) Serum total bilirubin > 1.5× ULN, unless related to lupus
iv) Hemoglobin < 8 g/dL (80 g/L) or, if due to hemolytic anemia related
to SLE, < 7 g/dL (70 g/L)
v) Proteinuria > 3.0 g/day (3000 mg/day) or equivalent level of
proteinuria as assessed by UCPR (3 mg/mg or 339 mg/mmol)
vi) Estimated glomerular filtration rate < 30 mL/min
vii) Absolute white blood cell count < 1.2× 103/μL (1.2× 109/L)
viii) Platelet count < 50× 103/μL (50× 109/L)
ix) Abnormal free thyroxine (T4). Those with abnormal free T4 will be
excluded unless they have a prior diagnosis of a thyroid disorder and are
currently receiving thyroid replacement therapy.
6) History of any significant drug allergy |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of subjects who meet response criteria for SRI(4) at Week 32. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Efficacy:
-Proportion of subjects who achieve a British Isles Lupus Assessment
Group-based Composite Lupus Assessment (BICLA) response at Week 32
after treatment with BMS-986165 or placebo administered on stable
background therapy
- Proportion of subjects with a Cutaneous Lupus Erythematosus Disease
Area and Severity Index (CLASI) activity score ≥ 10 at baseline who
achieve a CLASI response, defined as a decrease of ≥ 50% from baseline
CLASI activity score
- Change from baseline in the 40-joint count for tender, swollen, and
tender + swollen joints
Safety:
- Number and proportion of subjects experiencing serious adverse
events (SAEs), AEs, and abnormalities in laboratory testing, vital signs,
and electrocardiograms (ECGs)
Pharmacokinetics:
Trough concentrations of BMS-986165
Pharmacodynamics:
-Change in mean and median interferon-regulated gene (IRG)
expression levels
compared to baseline over time and at Week 32
-Change in mean complement (C3, C4) and anti-double-stranded DNA
(dsDNA)
levels compared to baseline over time and at Week 32
-Assess the effect of BMS-986165 on measures of global SLE clinical
response in
subjects based on IRG status (ie, high versus low IRG signature) at
Week 32. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy - Week 32
Safety - Throughout the study
Pharmacokinetics - at Weeks 2, 4, 8, 12, 24, 32, and 48
Pharmacodynamics - Week 32 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 37 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Colombia |
Israel |
Japan |
Korea, Republic of |
Mexico |
Taiwan |
United States |
France |
Poland |
Bulgaria |
Romania |
Germany |
Hungary |
Russian Federation |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 7 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 7 |